Recently, the real-world clinical study data of Hansoh Xinfu® (Flumatinib Mesylate Tablets) was shared at Hansoh's Spring Forum on Blood 2021. Attending experts highly recognized the remarkable efficacy and excellent clinical performance of Hansoh Xinfu®.
Hansoh Xinfu® (Flumatinib Mesylate Tablets)
01 High response rate and good efficacy
The latest clinical data on real-world first-line and post-first-line treatment with Hansoh Xinfu® was released at this forum. The data showed that Hansoh Xinfu® has significant clinical efficacy. In the treatment of chronic myeloid leukemia (CML), the lower the proportion of BCR/ABL fusion genes (BCR-ABL/ABLIS),, the higher the drug response rate and the better the treatment effect. In the first-line and post-first-line treatment with Hansoh Xinfu®, the proportion of BCR-ABL/ABLIS in most patients is very low, which also means that Hansoh Xinfu® has a high response rate and significant treatment effect in real-world CML treatment, which provides a better treatment option for CML patients.
02 Excellent safety and higher compliance
At the same time, real-world data showed that Hansoh Xinfu® has a good safety profile. Diarrhea and rash are common adverse reactions in the clinical treatment of CML patients. A high response rate will undoubtedly affect the quality of life of patients, reduce their treatment compliance and affect the overall treatment effect. However, according to real-world clinical data, Hansoh Xinfu® has a significantly lower incidence of adverse reactions related to patients' quality of life, such as diarrhea and rash, and no second-generation TKI-specific adverse reactions have occurred, resulting in a better safety profile. Better patient tolerance and higher treatment compliance will also have a positive impact on treatment.
Gold shines brighter after coming out from fire. As the first novel second-generation chronic myeloid leukemia drug independently developed in China, Hansoh Xinfu® is "bi-directionally optimized" in terms of efficacy and safety. It is a "second-generation +" tyrosine kinase inhibitor (TKI), with higher response rate, faster and deeper response, and better tolerance. Starting from March 1, 2021, the new version of the National Reimbursable Drug List has come into effect; Hansoh Xinfu® is now a reimbursable drug, from which more patients will benefit.
As an innovation-driven Chinese pharmaceutical company, Hansoh Pharma has successfully marketed four national Class 1 innovative drugs and has nearly 20 innovative drugs in various stages of clinical study. In addition, the company is actively developing in the field of biopharmaceuticals, and is applying international cutting-edge technology for the development and commercialization of innovative biopharmaceuticals. In the future, Hansoh Pharma will continue to explore and tackle key problems, keep innovating to address unmet clinical needs, and bring better disease solutions and treatment options to doctors and patients.
Scene of Hansoh's Spring Forum on Blood 2021